难治性抑郁症:遗传因素在临床分层与治疗个体化视角下的作用
本文综述难治性抑郁症(TRD)的遗传学证据,指出基于常见遗传变异的遗传度估计约为8%,但仅有六项全基因组关联研究发表且无位点或基因水平重复信号。作者强调TRD定义不一致和样本异质性可部分解释结果矛盾,建议按临床和生物学特征将TRD分组以提高可重复性,并助力靶向治疗开发或现有药物的个体化处方。
要点
- TRD基于常见遗传变异的遗传度估计约为8%,但全基因组关联研究仅六项且无重复信号。
- TRD定义不一致和样本差异可部分解释遗传重叠等结果的不一致。
- 作者认为应将TRD按临床和生物学特征分组以提高可重复性,助力个体化治疗。
核心结论
- TRD具有遗传成分,基于无亲缘个体常见遗传变异的估计约为8%。
- 既往仅六项TRD全基因组关联研究发表,未发现位点或基因水平重复信号,且TRD与其他性状的遗传重叠报告了看似相反的结果。
- TRD定义不一致和样本差异可部分解释结果不一致,不同TRD定义不应期望有相似的遗传特征。
- 作者认为可将整个TRD组按临床和生物学特征划分为亚组以提高可重复性,这可能是开发/重定位靶向治疗或辅助现有药物更个体化处方的关键因素。
研究设计与样本
- 本文为综述,围绕TRD遗传因素在临床分层和治疗个体化中的作用进行论述。
主要发现
- TRD与慢性抑郁、自杀行为和降低的生活质量相关。
- 基于无亲缘个体常见遗传变异估计TRD遗传度约为8%。
- 仅六项TRD全基因组关联研究发表,未发现位点或基因水平重复信号。
- TRD与其他性状的遗传重叠报告了看似相反的结果。
- 既往研究除效力有限外,对TRD异质性考虑不足,TRD可能包含不同组群,谈论TRDs可能更合适。
关键数值与推荐
- TRD基于常见遗传变异的遗传度估计约为8%。
- 已发表的TRD全基因组关联研究仅六项。
临床怎么用
- 作者认为按临床和生物学特征将TRD分组可提高可重复性,并可能助力开发/重定位靶向治疗或辅助现有药物更个体化处方。
- 作者指出当前临床实践 largely 集中于处方有限数量的抗抑郁药,相较于可用药物。
局限性
- 既往TRD全基因组关联研究效力有限。
- 既往研究对TRD异质性考虑不足。
- TRD定义不一致和样本差异可部分解释结果不一致。
- TRD与其他性状遗传重叠的报告结果看似相反。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Treatment-resistant depression (TRD) is associated with chronic depression, suicidal behaviours, and reduced quality of life. TRD has a demonstrated genetic component, estimated around 8% based on common genetic variation in unrelated individuals. However, only six genome-wide association studies of TRD were published, and no replicated signals at locus or gene level have been identified; furthermore, apparently opposite results were reported in terms of genetic overlap between TRD and other traits. Other than limited power, an important issue of previous studies was the scarce consideration of TRD heterogeneity, as TRD likely comprises different groups and talking about TRDs could be more appropriate. This review points out important issues in the definition of TRD and differences across samples included in previous studies, which can be partly responsible for the inconsistency across results. Different definitions of TRD should not be expected to have similar genetic profiles, and the whole TRD group can partitioned into subgroups, based on clinical and biological features, to increase reproducibility, as exemplified by recent findings. This can be a key factor to develop/repurpose targeted treatments, or simply to aid a more personalised prescription of available medications compared to current clinical practice, that is largely concentrated on the prescription of a limited number of antidepressants compared to those available.
引用
- Fabbri C. Treatment-resistant depression: role of genetic factors in the perspective of clinical stratification and treatment personalisation. Mol Psychiatry. 2025. PMID: 39827221. doi:10.1038/s41380-025-02899-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。